Simeprevir

Manufactured by Johnson & Johnson

Sourced in Japan

Simeprevir is a direct-acting antiviral agent developed for the treatment of chronic hepatitis C virus (HCV) infection. It is a protease inhibitor that targets the HCV NS3/4A protease, a key enzyme required for viral replication.

Automatically generated - may contain errors

Lab products found in correlation

Daclatasvir, by Bristol-Myers Squibb (1 mentions) Ritonavir, by Abbvie (1 mentions) Ribavirin, by Roche (1 mentions) Ribavirin, by MSD (1 mentions) Peginterferon α 2b, by MSD (1 mentions)

2 protocols using simeprevir

Telaprevir and Simeprevir Combination Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

In the telaprevir group, all patients received combination therapy with peginterferon α-2b (1.0-1.5 μg/kg) weekly (MSD, Tokyo, Japan), ribavirin (MSD) and telaprevir (1,500 mg or 2,250 mg daily) (Tanabe-Mitsubishi, Tokyo, Japan) for 12 weeks, followed by 12 weeks of peginterferon α-2b and ribavirin. In the simeprevir group, patients received a combination treatment of simeprevir (100 mg daily) (Janssen Pharmaceutical K.K., Tokyo, Japan), peginterferonα-2a (180 μg) (Chugai, Tokyo, Japan) or peginterferon α-2b (1.0-1.5 μg/kg) weekly and ribavirin (MSD or Chugai) for 12 weeks, followed by 12 weeks of peginterferon α-2a or peginterferon α-2b and ribavirin. ribavirin was given orally at a daily dose of 400-1,000 mg based on body weight.

Kanda T., Nakamoto S., Sasaki R., Nakamura M., Yasui S., Haga Y., Ogasawara S., Tawada A., Arai M., Mikami S., Imazeki F, & Yokosuka O. (2016). Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. International Journal of Medical Sciences, 13(4), 310-315.

+ Open protocol

+ Expand

Hepatitis C Therapeutic Regimens Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Therapeutic regimens included Daclatasvir (Bristol-Myers Squibb S.r.l., Contrada Fontana del Ceraso, Italy), Ledipasvir (Gilead Sciences Ireland UC, Carrigtohill, Ireland), Simeprevir (Janssen-Cilag, Borgo San Michele, Italy), Sofosbuvir (Gilead Sciences Ireland UC, Carrigtohill, Ireland), the combination of Paritaprevir, Ritonavir and Ombitasvir (AbbVie Deutschland, Ludwigshafen, Germany) with or without Dasabuvir (AbbVie Deutschland, Ludwigshafen, Germany) and Velpatasvir (Gilead Sciences Ireland UC, Carrigtohill, Ireland) and Ribavirin (Roche Pharma, Grenzach-Wyhlen, Germany). All medications were administered as recommended by the manufacturer. The

Weidner P., Boettche D., Zimmerer T., Burgermeister E., Teufel A., Ebert M.P.A, & Antoni C. (2018). Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C. Journal of gastrointestinal and liver diseases : JGLD, 27(3).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!